HauserSLWaubantEArnoldDLVollmerTAntelJFoxRJ. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med2008; 358: 676–688.
2.
RollPArumugamPKneitzCDornerTHans-PeterT. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum2006; 54: 2377–2386.
3.
CarsonKEvensARicheyEHabermannTFocosiDSeymourJ. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood2009; 14: 4834–4840.
4.
FleischmannRM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient withrheumatoid arthritis. Arthritis Rheum2009; 60: 3225–3228.
5.
CliffordDAncesBCostelloCRosen-SchmidtSAnderssonMParksD. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol2011; [ePub ahead of print].
6.
Bar-OrACalabresiPAArnoldDMarkowitzCShaferSKasperLH. Rituximab in relapsing–remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol2008; 63: 395–400.
